What Satsuma Pharmaceuticals does

Satsuma Pharmaceuticals is a biopharmaceutical company that develops and is preparing to commercialize therapeutics for the acute treatment of migraine. Founded in 2016 and headquartered in Durham, North Carolina (Research Triangle Park), the company was spun out of Japanese CRO Shin Nippon Biomedical Laboratories (SNBL) in January 2017 with a $12 million Series A, IPO'd on NASDAQ under ticker STSA in September 2019, and was taken private by parent SNBL in June 2023 after a tender offer. As of the most recent data, Satsuma continues active operations as a wholly-owned subsidiary of SNBL.

Its core asset is Atzumi (formerly STS101), an FDA-approved (April 30, 2025) dihydroergotamine nasal powder indicated for the acute treatment of migraine with or without aura in adults — the first and only DHE nasal powder on the market. The product is built on Satsuma's proprietary SMART (Simple MucoAdhesive Release Technology) platform, which pairs a dry-powder DHE formulation with a mucoadhesive drug carrier and engineered drug particle technology, delivered via a single-use, pre-filled nasal device. Phase 3 data (SUMMIT and ASCEND, totaling 1,500+ subjects and 10,000+ migraine attacks) demonstrated mean DHE plasma concentrations of 2.0 ng/mL within approximately 15-20 minutes, sustained levels above 1.0 ng/mL for 2 hours, freedom from pain and most bothersome symptoms at 2 hours, and durability of benefit through 48 hours.

The business model is prescription pharmaceutical sales of Atzumi through US pharmacy distribution channels, with go-to-market targeting neurologists and UCNS-certified headache specialists who treat acute migraine patients, particularly those who have failed oral therapies or cannot tolerate existing DHE formulations (Migranal liquid nasal spray, injectable DHE). Satsuma has appointed a Chief Commercial Officer, publishes in peer-reviewed headache journals, and presents at the American Headache Society Annual Scientific Meeting, but operates with only 1-10 employees and has not yet commenced commercial sales; no revenue is disclosed. Total equity raised across the Series A ($12M, 2017), Series B ($62M, April 2019), IPO (~$82.5–90.8M gross, September 2019), and a March 2021 follow-on ($80M) exceeded $235M.

Name

Satsuma Pharmaceuticals

Legal name

Satsuma Pharmaceuticals, Inc.

Website

https://satsumarx.com

Company type

Public

Founded year

2016

Operating status

Operating

Headcount range

1–10 employees

Short description

Satsuma Pharmaceuticals is a biopharmaceutical company that develops and is preparing to commercialize Atzumi, an FDA-approved dihydroergotamine nasal powder for the acute treatment of migraine in adults, using its proprietary SMART mucoadhesive dry-powder nasal delivery platform. It operates as a privately held subsidiary of Japan's SNBL.

Ownership category

akta.pro rank

Product category

Acute Migraine Therapeutics

NAICS

Medicinal and Botanical Manufacturing (325411)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Headache & Migraine Medicine (HLAKAIAE)

akta.pro secondary industry

Nasal Drug Delivery Devices (Sprays/Powder Devices) (HLAHAIAK)

Keywords

• Acute migraine treatment
• Nasal drug delivery
• Dihydroergotamine therapy
• Drug-device combinations
• Migraine therapeutics

Headquarters

HQ city

South San Francisco

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain

Revenue model

1. Pharmaceutical Product Sales (Atzumi): Satsuma's FDA-approved product Atzumi (dihydroergotamine nasal powder) for acute migraine treatment. The company is preparing for commercial launch in the United States. Product is not yet commercially available as of the available data.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Satsuma Pharmaceuticals develops and commercializes a novel therapeutic product for the acute treatment of migraine with or without aura in adults. Its FDA-approved product Atzumi (dihydroergotamine nasal powder, formerly STS101) is the first and only DHE nasal powder for acute migraine, combining a proprietary dry-powder formulation with an easy-to-use, single-use nasal delivery device built on the SMART (Simple MucoAdhesive Release Technology) platform.

Product overview

Satsuma Pharmaceuticals is a biopharmaceutical company with one FDA-approved product and a proprietary drug delivery technology platform. The company's flagship product is Atzumi™ (formerly known as STS101), a dihydroergotamine nasal powder for the acute treatment of migraine. This product leverages the SMART™ (Simple MucoAdhesive Release Technology) Platform, which combines a proprietary dry-powder formulation with an easy-to-use nasal delivery device. The technology is designed to overcome limitations of existing DHE products by providing better stability, adherence to nasal mucosa, and resistance to dripping compared to liquid formulations.

Differentiator

Problem solved

Functional benefit

Products and services

• Atzumi™ (dihydroergotamine nasal powder) FDA-approved prescription drug-device combination product delivering dihydroergotamine as a dry-powder nasal formulation for the acute treatment of migraine with or without aura in adults. It is designed to provide rapid, sustained relief with a single, self-administered dose using a pre-filled, single-use nasal device.

Quantifiable outcome

• Rapid pain relief: freedom from pain at 2 hours post-administration in Phase 3 studies
• +3 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators10 records

Recent moves9 records

Expansion highlights5 records

Broad incumbents

• AbbVie: Markets Ubrelvy (ubrogepant), an oral CGRP antagonist for acute migraine, providing a direct broad-incumbent comparable on prescriber audience, payer dynamics, and acute-migraine commercial strategy.
• Pfizer: Through its acquisition of Biohaven, Pfizer markets Nurtec ODT, a leading oral CGRP antagonist for acute migraine — the dominant oral alternative that Atzumi must compete against or complement.
• Teva Pharmaceutical Industries: Markets Migranal (DHE liquid nasal spray) for acute migraine, the legacy product Atzumi is being positioned against, and a broad incumbent in migraine and CNS therapeutics.
• Lundbeck: Markets Vyepti (eptinezumab) and acquired Alder Biopharmaceuticals; relevant as a broad migraine incumbent with established headache-specialist sales coverage comparable to Satsuma's target audience.
• Eli Lilly: Commercializes Reyvow (lasmiditan) and Emgality for migraine, representing the large-pharma CGRP-era standard of care that defines the competitive backdrop for Atzumi's launch.

Direct peers

• Impel Pharmaceuticals: Developer of Trudhesa, a DHE mesylate nasal spray approved for acute migraine — the closest direct competitor to Atzumi in the non-oral DHE acute-migraine category and head-to-head on the same prescribers (neurologists/headache specialists).
• Axsome Therapeutics: Commercial-stage CNS company with acute migraine and headache adjacencies — comparable as a focused neurology therapeutics commercializer targeting prescribers of acute migraine products.
• Tonix Pharmaceuticals: Specialty CNS pharmaceutical company with active migraine therapeutic programs, providing a comparable small-cap neurology-focused drug development and commercialization profile to Satsuma.

Emerging players

• Collegium Pharmaceutical: Specialty pharma commercializing pain and CNS therapeutics with a similar small/mid-cap US sales force profile; relevant as a model for how a focused company can capture share in a neurologically-prescribed category.

Others

• Shin Nippon Biomedical Laboratories (SNBL): Satsuma's parent company and a Japan-listed translational CRO with proprietary intranasal drug-delivery technology — comparable as the originator of the SMART platform and the strategic counterparty that took Satsuma private.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/satsuma-pharmaceuticals-inc

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds3 records

Investors18 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Satsuma Pharmaceuticals